

# Inhibition of the B7-H3 immune checkpoint limits tumor lymphocyte function

Cell Research

27, 1034-1045

DOI: [10.1038/cr.2017.90](https://doi.org/10.1038/cr.2017.90)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Natural Killer Cells: Angels and Devils for Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2017, 18, 1868.	1.8	59
2	The State of Cellular Adoptive Immunotherapy for Neuroblastoma and Other Pediatric Solid Tumors. <i>Frontiers in Immunology</i> , 2017, 8, 1640.	2.2	7
3	Reduced sB7-H3 Expression in the Peripheral Blood of Systemic Lupus Erythematosus Patients. <i>Journal of Immunology Research</i> , 2017, 2017, 1-8.	0.9	11
4	Nanotherapeutic approaches targeting angiogenesis and immune dysfunction in tumor microenvironment. <i>Science China Life Sciences</i> , 2018, 61, 380-391.	2.3	15
5	Polymorphisms of nucleotide factor of activated T cells cytoplasmic 2 and 4 and the risk of acute rejection following kidney transplantation. <i>World Journal of Urology</i> , 2018, 36, 111-116.	1.2	13
6	PD-1 expression and clinical PD-1 blockade in B-cell lymphomas. <i>Blood</i> , 2018, 131, 68-83.	0.6	311
7	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. <i>Translational Lung Cancer Research</i> , 2018, 7, 691-702.	1.3	8
8	Large-scale analysis reveals the specific clinical and immune features of B7-H3 in glioma. <i>OncImmunology</i> , 2018, 7, e1461304.	2.1	59
9	Genetic and clinical characterization of B7-H3 (CD276) expression and epigenetic regulation in diffuse brain glioma. <i>Cancer Science</i> , 2018, 109, 2697-2705.	1.7	73
10	Cancer Immunotherapy: A Focus on the Regulation of Immune Checkpoints. <i>International Journal of Molecular Sciences</i> , 2018, 19, 1389.	1.8	77
11	Clinical significance of serum soluble B7-H3 in patients with osteosarcoma. <i>Cancer Cell International</i> , 2018, 18, 115.	1.8	24
12	Expression of the inhibitory B7 family molecule VISTA in human colorectal carcinoma tumors. <i>Cancer Immunology, Immunotherapy</i> , 2018, 67, 1685-1694.	2.0	81
13	B7-H3 modulates endothelial cell angiogenesis through the VEGF cytokine. <i>Immunologic Research</i> , 2019, 67, 202-211.	1.3	13
14	Interleukin-17D Promotes Pathogenicity During Infection by Suppressing CD8 T Cell Activity. <i>Frontiers in Immunology</i> , 2019, 10, 1172.	2.2	31
15	High-resolution structural genomics reveals new therapeutic vulnerabilities in glioblastoma. <i>Genome Research</i> , 2019, 29, 1211-1222.	2.4	52
16	Immune Checkpoints of the B7 Family. Part 2. Representatives of the B7 Family B7-H3, B7-H4, B7-H5, B7-H6, B7-H7, and ILDR2 and Their Receptors. <i>Russian Journal of Bioorganic Chemistry</i> , 2019, 45, 321-334.	0.3	9
17	Monoclonal Antibodies in Dermatoonology – State of the Art and Future Perspectives. <i>Cancers</i> , 2019, 11, 1420.	1.7	9
18	Expression of Programmed Cell Death-Ligands in Hepatocellular Carcinoma: Correlation With Immune Microenvironment and Survival Outcomes. <i>Frontiers in Oncology</i> , 2019, 9, 883.	1.3	40

#	ARTICLE	IF	CITATIONS
19	B7-H3 as a Novel CAR-T Therapeutic Target for Glioblastoma. <i>Molecular Therapy - Oncolytics</i> , 2019, 14, 279-287.	2.0	120
20	Bispecific anti-CD3xanti-B7-H3 antibody mediates T cell cytotoxic ability to human melanoma in vitro and in vivo. <i>Investigational New Drugs</i> , 2019, 37, 1036-1043.	1.2	19
21	B7-H3 and its role in bone cancers. <i>Pathology Research and Practice</i> , 2019, 215, 152420.	1.0	14
22	Frequent B7-H3 overexpression in craniopharyngioma. <i>Biochemical and Biophysical Research Communications</i> , 2019, 514, 379-385.	1.0	10
23	Cancer stemness, intratumoral heterogeneity, and immune response across cancers. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 9020-9029.	3.3	372
24	Autophagy protein ATG5 regulates CD36 expression and anti-tumor MHC class II antigen presentation in dendritic cells. <i>Autophagy</i> , 2019, 15, 2091-2106.	4.3	61
25	&lt;p&gt;Growth and differentiation factor 15 regulates PD-L1 expression in glioblastoma&lt;/p&gt;. <i>Cancer Management and Research</i> , 2019, Volume 11, 2653-2661.	0.9	20
26	Fcγ3R-Binding Is an Important Functional Attribute for Immune Checkpoint Antibodies in Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2019, 10, 292.	2.2	111
27	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 via Chimeric Antigen Receptor T Cells. <i>Cancer Cell</i> , 2019, 35, 221-237.e8.	7.7	286
28	Tracers for non-invasive radionuclide imaging of immune checkpoint expression in cancer. <i>EJNMMI Radiopharmacy and Chemistry</i> , 2019, 4, 29.	1.8	23
29	Future of Immune Checkpoint Inhibitors. , 2019, , 227-243.		2
30	B7-H3 promotes multiple myeloma cell survival and proliferation by ROS-dependent activation of Src/STAT3 and c-Cbl-mediated degradation of SOCS3. <i>Leukemia</i> , 2019, 33, 1475-1486.	3.3	47
31	Expression of Programmed Death-Ligand 1 in Laryngeal Carcinoma and its Effects on Immune Cell Subgroup Infiltration. <i>Pathology and Oncology Research</i> , 2019, 25, 1437-1443.	0.9	8
32	Tumor-expressed B7-H3 mediates the inhibition of antitumor T-cell functions in ovarian cancer insensitive to PD-1 blockade therapy. <i>Cellular and Molecular Immunology</i> , 2020, 17, 227-236.	4.8	66
34	T cell cytotoxicity toward hematologic malignancy via B7-H3 targeting. <i>Investigational New Drugs</i> , 2020, 38, 722-732.	1.2	12
35	The New Immunotherapy Combinations in the Treatment of Advanced Non-Small Cell Lung Cancer: Reality and Perspectives. <i>Current Clinical Pharmacology</i> , 2020, 15, 11-19.	0.2	14
36	B7-H3 expression in upper tract urothelial carcinoma associates with adverse clinicopathological features and poor survival. <i>Pathology Research and Practice</i> , 2020, 216, 153219.	1.0	7
37	Expression status of PD-L1 and B7-H3 in mesothelioma. <i>Pathology International</i> , 2020, 70, 999-1008.	0.6	13

#	ARTICLE	IF	CITATIONS
38	Knocking down B7H3 expression enhances cell proliferation of SHEDs via the SHP1/AKT signal axis. <i>Biochemical and Biophysical Research Communications</i> , 2020, 531, 282-289.	1.0	4
39	Hybrid spherical nucleotide nanoparticles can enhance the synergistic anti-tumor effect of CTLA-4 and PD-1 blockades. <i>Biomaterials Science</i> , 2020, 8, 4757-4766.	2.6	9
40	Protein Kinase C Isozymes Associated With Relapse Free Survival in Non-Small Cell Lung Cancer Patients. <i>Frontiers in Oncology</i> , 2020, 10, 590755.	1.3	6
41	The Role of TIM-3 in Hepatocellular Carcinoma: A Promising Target for Immunotherapy?. <i>Frontiers in Oncology</i> , 2020, 10, 601661.	1.3	28
42	High B7H3 expression is linked to increased risk of prostate cancer progression. <i>Pathology International</i> , 2020, 70, 733-742.	0.6	16
43	Knockdown of lncRNA MCM3AP-AS1 Attenuates Chemoresistance of Burkitt Lymphoma to Doxorubicin Treatment via Targeting the miR-15a/EIF4E Axis. <i>Cancer Management and Research</i> , 2020, Volume 12, 5845-5855.	0.9	21
44	Transcriptome analysis of desmoplastic small round cell tumors identifies actionable therapeutic targets: a report from the Children's Oncology Group. <i>Scientific Reports</i> , 2020, 10, 12318.	1.6	28
45	Monocyte-derived APCs are central to the response of PD1 checkpoint blockade and provide a therapeutic target for combination therapy. , 2020, 8, e000588.		38
46	Targeting B7-H3 Immune Checkpoint With Chimeric Antigen Receptor-Engineered Natural Killer Cells Exhibits Potent Cytotoxicity Against Non-Small Cell Lung Cancer. <i>Frontiers in Pharmacology</i> , 2020, 11, 1089.	1.6	38
47	CAR T Cell Therapy for Pediatric Brain Tumors. <i>Frontiers in Oncology</i> , 2020, 10, 1582.	1.3	37
48	Alternative Checkpoints as Targets for Immunotherapy. <i>Current Oncology Reports</i> , 2020, 22, 126.	1.8	12
49	B7-H3-Targeted CAR-T Cells Exhibit Potent Antitumor Effects on Hematologic and Solid Tumors. <i>Molecular Therapy - Oncolytics</i> , 2020, 17, 180-189.	2.0	67
50	Potential Therapeutic Targets of B7 Family in Colorectal Cancer. <i>Frontiers in Immunology</i> , 2020, 11, 681.	2.2	25
51	Clinicopathological and molecular features of hereditary leiomyomatosis and renal cell cancer-associated renal cell carcinomas. <i>Journal of Clinical Pathology</i> , 2020, 73, 819-825.	1.0	13
52	Current Advances in Osteosarcoma. <i>Advances in Experimental Medicine and Biology</i> , 2020, , .	0.8	4
53	Metastatic melanoma: therapeutic agents in preclinical and early clinical development. <i>Expert Opinion on Investigational Drugs</i> , 2020, 29, 739-753.	1.9	2
54	B7-H3 immune checkpoint expression is a poor prognostic factor in colorectal carcinoma. <i>Modern Pathology</i> , 2020, 33, 2330-2340.	2.9	25
55	B7-H3 Regulates Glioma Growth and Cell Invasion Through a JAK2/STAT3/Slug-Dependent Signaling Pathway. <i>OncoTargets and Therapy</i> , 2020, Volume 13, 2215-2224.	1.0	35

#	ARTICLE	IF	CITATIONS
56	MHC Class I Downregulation in Cancer: Underlying Mechanisms and Potential Targets for Cancer Immunotherapy. <i>Cancers</i> , 2020, 12, 1760.	1.7	213
57	B7-H3: A promising therapeutic target for autoimmune diseases. <i>Cellular Immunology</i> , 2020, 352, 104077.	1.4	16
58	A novel chalcone derivative has antitumor activity in melanoma by inducing DNA damage through the upregulation of ROS products. <i>Cancer Cell International</i> , 2020, 20, 36.	1.8	17
59	Clinicopathological and Prognostic Characteristics of CD276 (B7-H3) Expression in Adrenocortical Carcinoma. <i>Disease Markers</i> , 2020, 2020, 1-10.	0.6	12
60	Loss of <i>BAP1</i> expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development. <i>Journal of Pathology</i> , 2020, 250, 420-439.	2.1	97
61	B7-H3 inhibits the IFN- $\gamma$ -dependent cytotoxicity of $\text{V}\alpha 9\text{V}\beta 2$ T cells against colon cancer cells. <i>OncoImmunology</i> , 2020, 9, 1748991.	2.1	43
62	Efficacy of B7-H3-Redirected BiTE and CAR-T Immunotherapies Against Extranodal Nasal Natural Killer/T Cell Lymphoma. <i>Translational Oncology</i> , 2020, 13, 100770.	1.7	29
63	Natural-Killer-Derived Extracellular Vesicles: Immune Sensors and Interactors. <i>Frontiers in Immunology</i> , 2020, 11, 262.	2.2	87
64	B7-H3: An Attractive Target for Antibody-based Immunotherapy. <i>Clinical Cancer Research</i> , 2021, 27, 1227-1235.	3.2	162
65	Targeting tumor-associated macrophages as an antitumor strategy. <i>Biochemical Pharmacology</i> , 2021, 183, 114354.	2.0	88
66	B7-H3 targeted antibody-based immunotherapy of malignant diseases. <i>Expert Opinion on Biological Therapy</i> , 2021, 21, 587-602.	1.4	16
67	B7-H3 confers resistance to $\text{V}\alpha 9\text{V}\beta 2$ T cell-mediated cytotoxicity in human colon cancer cells via the STAT3/ULBP2 axis. <i>Cancer Immunology, Immunotherapy</i> , 2021, 70, 1213-1226.	2.0	11
68	CD276 as a novel CAR NK-92 therapeutic target for neuroblastoma. <i>Advances in Cell and Gene Therapy</i> , 2021, 4, e105.	0.6	18
69	B7-H3 augments the pro-angiogenic function of tumor-associated macrophages and acts as a novel adjuvant target for triple-negative breast cancer therapy. <i>Biochemical Pharmacology</i> , 2021, 183, 114298.	2.0	30
70	The Updated Status and Future Direction of Immunotherapy Targeting B7-H1/PD-1 in Osteosarcoma. <i>Cancer Management and Research</i> , 2021, Volume 13, 757-764.	0.9	0
71	Synergistic anti-tumor efficacy of oncolytic influenza viruses and B7-H3 immune-checkpoint inhibitors against IC-resistant lung cancers. <i>OncoImmunology</i> , 2021, 10, 1885778.	2.1	12
72	Targeting B7-H3 via chimeric antigen receptor T cells and bispecific killer cell engagers augments antitumor response of cytotoxic lymphocytes. <i>Journal of Hematology and Oncology</i> , 2021, 14, 21.	6.9	51
73	Gastric Carcinomas with Stromal B7-H3 Expression Have Lower Intratumoural CD8+ T Cell Density. <i>International Journal of Molecular Sciences</i> , 2021, 22, 2129.	1.8	14

#	ARTICLE	IF	CITATIONS
74	Tumor B7-H3 expression in diagnostic biopsy specimens and survival in patients with metastatic prostate cancer. <i>Prostate Cancer and Prostatic Diseases</i> , 2021, 24, 767-774.	2.0	13
75	Advanced Molecular Characterization Using Digital Spatial Profiling Technology on Immunooncology Targets in Methylated Compared with Unmethylated IDH-Wildtype Glioblastoma. <i>Journal of Oncology</i> , 2021, 2021, 1-9.	0.6	7
76	MYCN Drives a Tumor Immunosuppressive Environment Which Impacts Survival in Neuroblastoma. <i>Frontiers in Oncology</i> , 2021, 11, 625207.	1.3	21
77	Preclinical Evaluation of B7-H3-specific Chimeric Antigen Receptor T Cells for the Treatment of Acute Myeloid Leukemia. <i>Clinical Cancer Research</i> , 2021, 27, 3141-3153.	3.2	45
78	The B7-H3-Targeting Antibody-Drug Conjugate m276-SL-PBD Is Potently Effective Against Pediatric Cancer Preclinical Solid Tumor Models. <i>Clinical Cancer Research</i> , 2021, 27, 2938-2946.	3.2	55
79	B7 Family Members in Lymphoma: Promising Novel Targets for Tumor Immunotherapy?. <i>Frontiers in Oncology</i> , 2021, 11, 647526.	1.3	3
80	Enhancing CAR-T cell efficacy in solid tumors by targeting the tumor microenvironment. <i>Cellular and Molecular Immunology</i> , 2021, 18, 1085-1095.	4.8	74
81	Immunotherapy for osteosarcoma: Fundamental mechanism, rationale, and recent breakthroughs. <i>Cancer Letters</i> , 2021, 500, 1-10.	3.2	220
82	Immune Checkpoint-Associated Locations of Diffuse Gliomas Comparing Pediatric With Adult Patients Based on Voxel-Wise Analysis. <i>Frontiers in Immunology</i> , 2021, 12, 582594.	2.2	4
83	Expression patterns of the immune checkpoint ligand CD276 in urothelial carcinoma. <i>BMC Urology</i> , 2021, 21, 60.	0.6	10
84	Dysregulation of chromatin organization in pediatric and adult brain tumors: oncoepigenomic contributions to tumorigenesis and cancer stem cell properties. <i>Genome</i> , 2021, 64, 326-336.	0.9	1
85	Comprehensive Analysis of Myeloid Signature Genes in Head and Neck Squamous Cell Carcinoma to Predict the Prognosis and Immune Infiltration. <i>Frontiers in Immunology</i> , 2021, 12, 659184.	2.2	13
86	Cancer Cell B7-H3 Expression Is More Prevalent in the Pancreato-Biliary Subtype of Ampullary Cancer Than in Pancreatic Cancer. <i>Frontiers in Oncology</i> , 2021, 11, 615691.	1.3	3
87	FUT8-mediated aberrant N-glycosylation of B7H3 suppresses the immune response in triple-negative breast cancer. <i>Nature Communications</i> , 2021, 12, 2672.	5.8	74
88	Glycosylation of Immune Receptors in Cancer. <i>Cells</i> , 2021, 10, 1100.	1.8	32
89	Identification of m6A methyltransferase-related lncRNA signature for predicting immunotherapy and prognosis in patients with hepatocellular carcinoma. <i>Bioscience Reports</i> , 2021, 41, .	1.1	39
90	Approaches to Enhance Natural Killer Cell-Based Immunotherapy for Pediatric Solid Tumors. <i>Cancers</i> , 2021, 13, 2796.	1.7	13
91	Expression, regulation and clinical significance of B7-H3 on neutrophils in human gastric cancer. <i>Clinical Immunology</i> , 2021, 227, 108753.	1.4	12

#	ARTICLE	IF	CITATIONS
92	MicroRNA-326 attenuates immune escape and prevents metastasis in lung adenocarcinoma by targeting PD-L1 and B7-H3. <i>Cell Death Discovery</i> , 2021, 7, 145.	2.0	18
93	Tumor-Associated Macrophages: A Potential Target for Cancer Therapy. <i>Frontiers in Oncology</i> , 2021, 11, 693517.	1.3	46
94	Multiplexed digital spatial profiling of invasive breast tumors from Black and White women. <i>Molecular Oncology</i> , 2022, 16, 54-68.	2.1	12
95	Identification and Validation of an 11-Ferroptosis Related Gene Signature and Its Correlation With Immune Checkpoint Molecules in Glioma. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 652599.	1.8	20
96	Immune infiltration profiling in gastric cancer and their clinical implications. <i>Cancer Science</i> , 2021, 112, 3569-3584.	1.7	38
97	B7-H3/CD276: An Emerging Cancer Immunotherapy. <i>Frontiers in Immunology</i> , 2021, 12, 701006.	2.2	100
98	CD276 is an important player in macrophage recruitment into the tumor and an upstream regulator for PAI-1. <i>Scientific Reports</i> , 2021, 11, 14849.	1.6	6
99	MiR-29c downregulates tumor-expressed B7-H3 to mediate the antitumor NK-cell functions in ovarian cancer. <i>Gynecologic Oncology</i> , 2021, 162, 190-199.	0.6	19
100	Inhibitory Receptors and Immune Checkpoints Regulating Natural Killer Cell Responses to Cancer. <i>Cancers</i> , 2021, 13, 4263.	1.7	32
101	PLA2G4A promotes right-sided colorectal cancer progression by inducing CD39+ <sup>hi</sup> Treg polarization. <i>JCI Insight</i> , 2021, 6, .	2.3	26
102	Epigenetic Regulation of Immunotherapy Response in Triple-Negative Breast Cancer. <i>Cancers</i> , 2021, 13, 4139.	1.7	10
103	Immune Checkpoints in Cancers: From Signaling to the Clinic. <i>Cancers</i> , 2021, 13, 4573.	1.7	35
104	A Novel Treatment for Ewing's Sarcoma: Chimeric Antigen Receptor-T Cell Therapy. <i>Frontiers in Immunology</i> , 2021, 12, 707211.	2.2	9
105	CD276 expression enables squamous cell carcinoma stem cells to evade immune surveillance. <i>Cell Stem Cell</i> , 2021, 28, 1597-1613.e7.	5.2	127
106	Surfaceome Profiling of Rhabdomyosarcoma Reveals B7-H3 as a Mediator of Immune Evasion. <i>Cancers</i> , 2021, 13, 4528.	1.7	14
108	Effective killing of cells expressing CD276 (B7-H3) by a bispecific T cell engager based on a new fully human antibody. <i>Translational Oncology</i> , 2021, 14, 101232.	1.7	6
109	Melphalan flufenamide inhibits osteoclastogenesis by suppressing proliferation of monocytes. <i>Bone Reports</i> , 2021, 15, 101098.	0.2	0
110	A Comprehensive Analysis of Baseline Clinical Characteristics and Biomarkers Associated with Outcome in Advanced Melanoma Patients Treated with Pembrolizumab. <i>Cancers</i> , 2021, 13, 168.	1.7	24

#	ARTICLE	IF	CITATIONS
111	Therapeutic targeting of TGF- $\beta$ 2 in cancer: hacking a master switch of immune suppression. <i>Clinical Science</i> , 2021, 135, 35-52.	1.8	42
112	Update of early phase clinical trials in cancer immunotherapy. <i>BMB Reports</i> , 2021, 54, 70-88.	1.1	27
113	B7-H3 $\times$ 4-1BB bispecific antibody augments antitumor immunity by enhancing terminally differentiated CD8 <sup>+</sup> tumor-infiltrating lymphocytes. <i>Science Advances</i> , 2021, 7, .	4.7	31
114	Genetically Modified T-Cell Therapy for Osteosarcoma: Into the Roaring 2020s. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1257, 109-131.	0.8	7
115	Effects of B7-H3 expression on tumour-infiltrating immune cells and clinicopathological characteristics in non-small-cell lung cancer. <i>European Journal of Cancer</i> , 2020, 133, 74-85.	1.3	38
116	Blocking PD-1/PD-L1 by an ADCC enhanced anti-B7-H3/PD-1 fusion protein engages immune activation and cytotoxicity. <i>International Immunopharmacology</i> , 2020, 84, 106584.	1.7	13
117	Prognostic value of immune checkpoint molecules in breast cancer. <i>Bioscience Reports</i> , 2020, 40, .	1.1	80
119	B7-H3-Induced Signaling in Lung Adenocarcinoma Cell Lines with Divergent Epidermal Growth Factor Receptor Mutation Patterns. <i>BioMed Research International</i> , 2020, 2020, 1-8.	0.9	7
120	Antitumor Responses in the Absence of Toxicity in Solid Tumors by Targeting B7-H3 Via Chimeric Antigen Receptor T Cells. <i>SSRN Electronic Journal</i> , 0, .	0.4	1
121	Manipulation of the Immune System for Cancer Defeat: A Focus on the T Cell Inhibitory Checkpoint Molecules. <i>Current Medicinal Chemistry</i> , 2020, 27, 2402-2448.	1.2	12
122	B7-H3-targeted Radioimmunotherapy of Human Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 4016-4038.	1.2	5
123	B7-H3 Immune Checkpoint Protein in Human Cancer. <i>Current Medicinal Chemistry</i> , 2020, 27, 4062-4086.	1.2	50
124	Cyclin-dependent kinase 9 expression and its association with CD8 <sup>+</sup> T cell infiltration in microsatellite-stable colorectal cancer. <i>Oncology Letters</i> , 2019, 18, 6046-6056.	0.8	10
125	Main NK cell receptors and their ligands: regulation by microRNAs. <i>AIMS Allergy and Immunology</i> , 2018, 2, 98-112.	0.3	6
126	The role of B7-H3 in tumors and its potential in clinical application. <i>International Immunopharmacology</i> , 2021, 101, 108153.	1.7	22
130	Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma. <i>Frontiers in Immunology</i> , 2021, 12, 757047.	2.2	8
131	The expressions and significance of B7-H3 and CTLA-4 in the clinical stages of non-small-cell lung cancer. <i>International Journal of Clinical and Experimental Pathology</i> , 2019, 12, 3032-3041.	0.5	0
132	B7-H3 Suppresses Antitumor Immunity via the CCL2 $\times$ CCR2 $\times$ M2 Macrophage Axis and Contributes to Ovarian Cancer Progression. <i>Cancer Immunology Research</i> , 2022, 10, 56-69.	1.6	49



#	ARTICLE	IF	CITATIONS
133	The importance of immune checkpoints in immune monitoring: A future paradigm shift in the treatment of cancer. <i>Biomedicine and Pharmacotherapy</i> , 2022, 146, 112516.	2.5	38
134	Cancer exosomes and natural killer cells dysfunction: biological roles, clinical significance and implications for immunotherapy. <i>Molecular Cancer</i> , 2022, 21, 15.	7.9	38
135	Over-Expression and Prognostic Significance of FN1, Correlating With Immune Infiltrates in Thyroid Cancer. <i>Frontiers in Medicine</i> , 2021, 8, 812278.	1.2	14
136	Breast Cancer Tumor Microenvironment and Molecular Aberrations Hijack Tumoricidal Immunity. <i>Cancers</i> , 2022, 14, 285.	1.7	12
137	The Prognostic Value of the Prognostic Nutritional Index in Operable High-Grade Glioma Patients and the Establishment of a Nomogram. <i>Frontiers in Oncology</i> , 2021, 11, 724769.	1.3	3
138	Pediatric medulloblastoma express immune checkpoint B7-H3. <i>Clinical and Translational Oncology</i> , 2022, , .	1.2	11
139	GOLM1 as a Potential Therapeutic Target Modulates B7-H3 Secretion to Drive Ovarian Cancer Metastasis. <i>Evidence-based Complementary and Alternative Medicine</i> , 2022, 2022, 1-12.	0.5	1
140	Expression Profiles and Prognostic Value of Multiple Inhibitory Checkpoints in Head and Neck Lymphoepithelioma-Like Carcinoma. <i>Frontiers in Immunology</i> , 2022, 13, 818411.	2.2	1
141	Mechanisms of immune activation and regulation: lessons from melanoma. <i>Nature Reviews Cancer</i> , 2022, 22, 195-207.	12.8	101
142	LINC01123 promotes immune escape by sponging miR-214-3p to regulate B7-H3 in head and neck squamous-cell carcinoma. <i>Cell Death and Disease</i> , 2022, 13, 109.	2.7	17
143	An Inflammatory Response Related Gene Signature Associated with Survival Outcome and Gemcitabine Response in Patients with Pancreatic Ductal Adenocarcinoma. <i>Frontiers in Pharmacology</i> , 2021, 12, 778294.	1.6	13
144	CAR T targets and microenvironmental barriers of osteosarcoma. <i>Cytotherapy</i> , 2022, 24, 567-576.	0.3	11
145	CAR <sup>T</sup> cell therapy for lung cancer: Potential and perspective. <i>Thoracic Cancer</i> , 2022, 13, 889-899.	0.8	25
146	Association of B7-H3 expression with racial ancestry, immune cell density, and androgen receptor activation in prostate cancer. <i>Cancer</i> , 2022, 128, 2269-2280.	2.0	16
147	Evidence supporting a role for the immune checkpoint protein B7-H3 in NK cell-mediated cytotoxicity against AML. <i>Blood</i> , 2022, 139, 2782-2796.	0.6	11
148	Microbiota-dependent activation of the myeloid calcineurin-NFAT pathway inhibits B7H3- and B7H4-dependent anti-tumor immunity in colorectal cancer. <i>Immunity</i> , 2022, 55, 701-717.e7.	6.6	16
149	Exploring the Mechanisms Underlying the Cardiotoxic Effects of Immune Checkpoint Inhibitor Therapies. <i>Vaccines</i> , 2022, 10, 540.	2.1	8
150	Establishment of an Ex Vivo Tissue Culture Model for Evaluation of Antitumor Efficacy in Clear Cell Renal Cell Carcinoma. <i>Frontiers in Oncology</i> , 2022, 12, 851191.	1.3	3

#	ARTICLE	IF	CITATIONS
151	Inhibitor of glutamine metabolism V9302 promotes ROS-induced autophagic degradation of B7H3 to enhance antitumor immunity. <i>Journal of Biological Chemistry</i> , 2022, 298, 101753.	1.6	19
152	B7-H3 Specific CAR T Cells for the Naturally Occurring, Spontaneous Canine Sarcoma Model. <i>Molecular Cancer Therapeutics</i> , 2022, 21, 999-1009.	1.9	8
153	Establishment of a mechanism-based in vitro coculture assay for evaluating the efficacy of immune checkpoint inhibitors. <i>Cancer Immunology, Immunotherapy</i> , 2022, , 1.	2.0	0
154	Dual checkpoint targeting of B7-H3 and PD-1 with enoblituzumab and pembrolizumab in advanced solid tumors: interim results from a multicenter phase I/II trial. , 2022, 10, e004424.		54
175	Elevated Expression of the Immune Checkpoint Ligand CD276 (B7-H3) in Urothelial Carcinoma Cell Lines Correlates Negatively with the Cell Proliferation. <i>International Journal of Molecular Sciences</i> , 2022, 23, 4969.	1.8	5
176	FLG Is a Potential Biomarker of Prognosis and Immunotherapy in Skin Cutaneous Melanoma. <i>Applied Bionics and Biomechanics</i> , 2022, 2022, 1-11.	0.5	3
178	Clinical Significance of B7-H3 and HER2 Co-Expression and Therapeutic Value of Combination Treatment in Gastric Cancer. <i>SSRN Electronic Journal</i> , 0, , .	0.4	0
179	Targeted Therapy of B7 Family Checkpoints as an Innovative Approach to Overcome Cancer Therapy Resistance: A Review from Chemotherapy to Immunotherapy. <i>Molecules</i> , 2022, 27, 3545.	1.7	1
180	AAMP is a binding partner of costimulatory human B7-H3. <i>Neuro-Oncology Advances</i> , 2022, 4, .	0.4	4
181	Immune checkpoint molecules in neuroblastoma: A clinical perspective. <i>Seminars in Cancer Biology</i> , 2022, 86, 247-258.	4.3	8
182	Chimeric Antigen Receptor (CAR)-T Cell Immunotherapy Against Thoracic Malignancies: Challenges and Opportunities. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	4
183	Clinical significance of B7-H3 and HER2 co-expression and therapeutic value of combination treatment in gastric cancer. <i>International Immunopharmacology</i> , 2022, 110, 108988.	1.7	6
184	Prognostic Value of Programmed Death Ligand-1 in Discriminating Patients With Lymph Nodeâ€“Negative, p53â€“Wild-Type, or Low-BRCA1/2-Expression Pancreatic Ductal Adenocarcinoma. <i>Archives of Pathology and Laboratory Medicine</i> , 2023, 147, 465-473.	1.2	2
185	The Regulatory Effects of MicroRNAs on Tumor Immunity. <i>BioMed Research International</i> , 2022, 2022, 1-12.	0.9	2
186	A B7-CD28 Family-Based Signature Demonstrates Significantly Different Prognosis and Immunological Characteristics in Diffuse Gliomas. <i>Frontiers in Molecular Biosciences</i> , 0, 9, .	1.6	1
187	FN1 overexpression is correlated with unfavorable prognosis and immune infiltrates in breast cancer. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	16
188	To kill a cancer: Targeting the immune inhibitory checkpoint molecule, B7-H3. <i>Biochimica Et Biophysica Acta: Reviews on Cancer</i> , 2022, 1877, 188783.	3.3	14
189	Engineering of immune checkpoints B7-H3 and CD155 enhances immune compatibility of MHC-lâ~/â~ iPSCs for I <sup>2</sup> cell replacement. <i>Cell Reports</i> , 2022, 40, 111423.	2.9	8

#	ARTICLE	IF	CITATIONS
190	Novel immune scoring dynamic nomograms based on B7-H3, B7-H4, and HHLA2: Potential prediction in survival and immunotherapeutic efficacy for gallbladder cancer. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	1
191	Advanced Acral Melanoma Therapies: Current Status and Future Directions. <i>Current Treatment Options in Oncology</i> , 2022, 23, 1405-1427.	1.3	9
192	B7-H3 as a Therapeutic Target in Advanced Prostate Cancer. <i>European Urology</i> , 2023, 83, 224-238.	0.9	18
193	Inhibiting PP2A Upregulates B7-H3 Expression and Potentially Increases the Sensitivity of Malignant Meningiomas to Immunotherapy by Proteomics. <i>Pathology and Oncology Research</i> , 0, 28, .	0.9	0
194	Bridging the Scientific Gaps to Identify Effective Treatments in Adrenocortical Cancer. <i>Cancers</i> , 2022, 14, 5245.	1.7	1
195	Predictive biomarkers in gastric cancer. <i>Journal of Cancer Research and Clinical Oncology</i> , 2023, 149, 467-481.	1.2	27
196	Regulation of autophagy fires up the cold tumor microenvironment to improve cancer immunotherapy. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	11
197	Tumor immune checkpoints and their associated inhibitors. <i>Journal of Zhejiang University: Science B</i> , 2022, 23, 823-843.	1.3	9
198	B7-H3 targeted CAR-T cells show highly efficient anti-tumor function against osteosarcoma both in vitro and in vivo. <i>BMC Cancer</i> , 2022, 22, .	1.1	6
199	Deficiency of tumor-expressed B7-H3 augments anti-tumor efficacy of anti-PD-L1 monotherapy rather than the combined chemoimmunotherapy in ovarian cancer. <i>Pharmacological Research</i> , 2022, 186, 106512.	3.1	4
200	A Novel Immune-Related Gene Prognostic Index (IRGPI) in Pancreatic Adenocarcinoma (PAAD) and Its Implications in the Tumor Microenvironment. <i>Cancers</i> , 2022, 14, 5652.	1.7	3
201	Lipid Nanoparticle Delivery System for mRNA Encoding B7H3-redirected Bispecific Antibody Displays Potent Antitumor Effects on Malignant Tumors. <i>Advanced Science</i> , 2023, 10, .	5.6	17
202	Pediatric versus adult high grade glioma: Immunotherapeutic and genomic considerations. <i>Frontiers in Immunology</i> , 0, 13, .	2.2	6
203	B7 Family Members in Pancreatic Ductal Adenocarcinoma: Attractive Targets for Cancer Immunotherapy. <i>International Journal of Molecular Sciences</i> , 2022, 23, 15005.	1.8	1
204	Bottlenecks and opportunities in immunotherapy for glioma: a narrative review. <i>Journal of Bio-X Research</i> , 0, Publish Ahead of Print, .	0.3	0
205	Transcriptomic and immunophenotypic profiling reveals molecular and immunological hallmarks of colorectal cancer tumorigenesis. <i>Gut</i> , 2023, 72, 1326-1339.	6.1	15
206	The Glycosylation of Immune Checkpoints and Their Applications in Oncology. <i>Pharmaceuticals</i> , 2022, 15, 1451.	1.7	3
207	Decreased B7-H3 promotes unexplained recurrent miscarriage via RhoA/ROCK2 signaling pathway and regulates the secretion of decidual NK cells. <i>Biology of Reproduction</i> , 2023, 108, 504-518.	1.2	6

#	ARTICLE	IF	CITATIONS
208	Inhibition of the B7-H3 immune checkpoint limits hepatocellular carcinoma progression by enhancing T lymphocyte-mediated immune cytotoxicity in vitro and in vivo. <i>Clinical and Translational Oncology</i> , 2023, 25, 1067-1079.	1.2	4
209	Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma. <i>Frontiers in Genetics</i> , 0, 13, .	1.1	2
210	Natural Killer Cell-Based Cancer Immunotherapy: From Bench to Bedside. , 0, , .		0
211	A glycolysis-related gene signatures in diffuse large B-Cell lymphoma predicts prognosis and tumor immune microenvironment. <i>Frontiers in Cell and Developmental Biology</i> , 0, 11, .	1.8	6
212	CAR T-cells to treat brain tumors. <i>Brain Research Bulletin</i> , 2023, 196, 76-98.	1.4	7
214	Comprehensive Analysis Reveals Distinct Immunological and Prognostic Characteristics of CD276/B7-H3 in Pan-Cancer. <i>International Journal of General Medicine</i> , 0, Volume 16, 367-391.	0.8	2
216	Prognostic value of prognostic nutritional index score and controlling nutritional status score in patients with glioblastoma: A comprehensive meta-analysis. <i>Frontiers in Oncology</i> , 0, 13, .	1.3	3
218	Recently approved and emerging monoclonal antibody immune checkpoint inhibitors for the treatment of advanced non-small cell lung cancer. <i>Expert Opinion on Biological Therapy</i> , 2023, 23, 261-268.	1.4	1
219	Managing the immune microenvironment of osteosarcoma: the outlook for osteosarcoma treatment. <i>Bone Research</i> , 2023, 11, .	5.4	38
220	mTORC1 upregulates B7-H3/CD276 to inhibit antitumor T cells and drive tumor immune evasion. <i>Nature Communications</i> , 2023, 14, .	5.8	10
221	EBV-Upregulated B7-H3 Inhibits NK cell-Mediated Antitumor Function and Contributes to Nasopharyngeal Carcinoma Progression. <i>Cancer Immunology Research</i> , 2023, 11, 830-846.	1.6	4
222	Neoadjuvant enoblituzumab in localized prostate cancer: a single-arm, phase 2 trial. <i>Nature Medicine</i> , 2023, 29, 888-897.	15.2	16
223	Potential role of LPAR5 gene in prognosis and immunity of thyroid papillary carcinoma and pan-cancer. <i>Scientific Reports</i> , 2023, 13, .	1.6	1
224	Immunotherapy for Pediatric Gliomas: CAR-T Cells Against B7H3: A Review of the Literature. <i>CNS and Neurological Disorders - Drug Targets</i> , 2024, 23, 420-430.	0.8	2
225	Patient-derived xenograft models in cancer therapy: technologies and applications. <i>Signal Transduction and Targeted Therapy</i> , 2023, 8, .	7.1	35
226	<scp>B7â€H3</scp> drives immunosuppression and Coâ€targeting with <scp>CD47</scp> is a new therapeutic strategy in Î²â€catenin activated melanomas. <i>Pigment Cell and Melanoma Research</i> , 2023, 36, 407-415.	1.5	1
248	Introduction on Immune Checkpoints in Cancer. , 2023, , 1-19.		0
250	The immune regulatory function of B7-H3 in malignancy: spotlight on the IFN-STAT1 axis and regulation of tumor-associated macrophages. <i>Immunologic Research</i> , 0, , .	1.3	0

#	ARTICLE	IF	CITATIONS
---	---------	----	-----------